Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Heppner

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Infection and Immunity|October 24, 2007
Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primatesS Pichyangkul, U Kum-Arb, K Yongvanitchit, et al.
The Journal of Infectious Diseases|February 15, 2001
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester, D A McKinney, N Tornieporth, et al.
Acta Tropica|September 30, 1997
SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in ThailandS Migasena, D G Heppner, D E Kyle, et al.
The Journal of Infectious Diseases|September 9, 1999
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in ThailandD S Walsh, S Looareesuwan, P Wilairatana, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
Vaccine|April 7, 2024
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adultsJ F Cummings, M E Polhemus, K E Kester, et al.
Tropical Medicine & International Health : TM & IH|January 9, 2007
Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in MozambiqueE Macete, J J Aponte, C Guinovart, et al.
The Journal of Infectious Diseases|August 1, 1996
Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomesD G Heppner, D M Gordon, M Gross, et al.
Journal of Clinical Microbiology|July 28, 2001
Malaria rapid diagnostic devices: performance characteristics of the ParaSight F device determined in a multisite field studyJ R Forney, A J Magill, C Wongsrichanalai, et al.
Vaccine|October 28, 2009
Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeysS Pichyangkul, P Tongtawe, U Kum-Arb, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Infection and Immunity|October 24, 2007
Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primatesS Pichyangkul, U Kum-Arb, K Yongvanitchit, et al.
The Journal of Infectious Diseases|February 15, 2001
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester, D A McKinney, N Tornieporth, et al.
Acta Tropica|September 30, 1997
SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in ThailandS Migasena, D G Heppner, D E Kyle, et al.
The Journal of Infectious Diseases|September 9, 1999
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in ThailandD S Walsh, S Looareesuwan, P Wilairatana, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
Vaccine|April 7, 2024
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adultsJ F Cummings, M E Polhemus, K E Kester, et al.
Tropical Medicine & International Health : TM & IH|January 9, 2007
Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in MozambiqueE Macete, J J Aponte, C Guinovart, et al.
The Journal of Infectious Diseases|August 1, 1996
Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomesD G Heppner, D M Gordon, M Gross, et al.
Journal of Clinical Microbiology|July 28, 2001
Malaria rapid diagnostic devices: performance characteristics of the ParaSight F device determined in a multisite field studyJ R Forney, A J Magill, C Wongsrichanalai, et al.
Vaccine|October 28, 2009
Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeysS Pichyangkul, P Tongtawe, U Kum-Arb, et al.
Pageof 4